Bausch Health Companies Inc (NYSE/TSX: BHC), a Canada-based multinational specialty pharmaceutical company, announced on Wednesday that it has received an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4mg/ml, from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland.
The product is intended to treat COVID-19 in adult and adolescent patients over 12 years of age and older, weighing around 40kg and in need of oxygen therapy. It is a corticosteroid that decreases inflammation.
The United States Food and Drug Administration (FDA) has not granted approval to Dexamethasone-containing products in the United States for the treatment for COVID-19. The products are only to be used in accordance with their approved label and under the directions of the patient's doctor.
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026